Headache (54%), irritability (38%), fatigue (34%), and nausea (30%) were the most common adverse events in compensated patients
anorexia (100%), fatigue (59%), neutropenia (53%), and thrombocytopenia (50%) were most common in decompensated patients
Based on
effectiveness and tolerability data, therapy has a significant effect in patients with compensated cirrhosis, while decompensated patients need to weigh the risks versus benefits of treatment.